Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 13, 2018

SELL
$46.46 - $68.49 $41,814 - $61,640
-900 Closed
0 $0
Q2 2018

Aug 10, 2018

SELL
$46.25 - $104.45 $205,812 - $464,802
-4,450 Reduced 83.18%
900 $44,000
Q1 2018

May 11, 2018

BUY
$57.4 - $108.44 $307,090 - $580,154
5,350 New
5,350 $568,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $247M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Compagnie Lombard Odier S Cm A Portfolio

Follow Compagnie Lombard Odier S Cm A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

News

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.